EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost‐Effectiveness of Steroids for Prolonging the Surgery‐Free Interval in Subglottic Stenosis

Jake A Langlie iD, Luke J Pasick, David E Rosow iD

The Laryngoscope · 2023

DOI: 10.1002/lary.30800 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, 2023. Verfasst von Jake A Langlie und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Laryngostenosis, Steroids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Repeat endoscopic dilation (ED) in the operating room for subglottic stenosis (SGS) remains an economic burden to patients. The cost‐effectiveness (CE) of adjuvant serial intralesional steroid injections (SILSI) to prolong the surgery‐free interval (SFI) in SGS patients requiring ED has yet to be studied.

Methods

Details of the cost of SILSI and ED were received from our tertiary academic center. SFI, cost of intervention, and the effect of SILSI on prolonging SFI were collected from a systematic review by Luke et al. SGS etiologies in the review included idiopathic, iatrogenic, or autoimmune. A break‐even analysis, comparing the cost of SILSI alone with the cost of repeat ED, was performed to determine if SILSI injections were cost‐effective in prolonging the SFI.

Results

Average extension of the SFI with SILSI was an additional 219.3 days compared to ED alone based on a systematic review of the literature. 41/55 (74.5%) cases did not require further ED once in‐office SILSI management began. SILSI administered in a 4‐dose series in 3‐to‐7‐week intervals (~$7,564.00) is CE if the reported recurrence rate of SGS requiring ED (~$39,429.00) has an absolute risk reduction (ARR) of at least 19.18% with the use of SILSI. Based on the literature, SILSI prevents ~3 out of every 4 cases of SGS at sufficient follow‐up from undergoing repeat ED, resulting in an ARR of ~75%.

Conclusions

SILSI is economically reasonable if it prolongs the SFI of at least one case of recurrence out of 5. SILSI, therefore, can be CE in extending the interval for surgical ED. Level of Evidence NA Laryngoscope , 133:3436–3442, 2023

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisLaryngostenosisSteroidsHumansConstriction, PathologicInjections, IntralesionalRetrospective StudiesTreatment OutcomeSystematic Reviews as Topic

Stichwörter der Autor:innen

adjuvant therapycost-effectivenessendoscopic dilationserial intralesionalsteroid injectionssubglottic stenosis

Substanzen

Steroids

Autor:innen und Institutionen

  • Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA.

ORCID-Profile: Jake A Langlie, David E Rosow

Zitieren

APA

Langlie, J. A., Pasick, L. J., & Rosow, D. E. (2023). Cost‐Effectiveness of Steroids for Prolonging the Surgery‐Free Interval in Subglottic Stenosis. The Laryngoscope. https://doi.org/10.1002/lary.30800

Vancouver

Langlie JA, Pasick LJ, Rosow DE. Cost‐Effectiveness of Steroids for Prolonging the Surgery‐Free Interval in Subglottic Stenosis. The Laryngoscope. 2023. doi:10.1002/lary.30800

BibTeX
@article{Langlie2023,
  author = {Langlie, Jake A and Pasick, Luke J and Rosow, David E},
  title = {Cost‐Effectiveness of Steroids for Prolonging the Surgery‐Free Interval in Subglottic Stenosis},
  journal = {The Laryngoscope},
  year = {2023},
  doi = {10.1002/lary.30800}
}
Kostenlos starten →